{"id":"NCT04650854","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis","officialTitle":"An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-03","primaryCompletion":"2024-01-25","completion":"2024-01-25","firstPosted":"2020-12-03","resultsPosted":"2025-04-18","lastUpdate":"2025-04-18"},"enrollment":165,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Myasthenia Gravis"],"interventions":[{"type":"DRUG","name":"Rozanolixizumab","otherNames":["UCB7665"]}],"arms":[{"label":"Rozanolixizumab dosage regimen 1","type":"EXPERIMENTAL"},{"label":"Rozanolixizumab dosage regimen 2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From Baseline (Day 1) to End of Study (up to 34 months)","effectByArm":[{"arm":"Rozanolixizumab ~7 mg/kg","deltaMin":78.4,"sd":null},{"arm":"Rozanolixizumab ~10 mg/kg","deltaMin":94.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":69,"countries":["United States","Canada","Czechia","Denmark","France","Georgia","Germany","Italy","Japan","Poland","Russia","Serbia","Spain","Taiwan"]},"refs":{"pmids":["40105996","37059507"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":8},"commonTop":["Headache","Diarrhoea","COVID-19","Pyrexia","Nausea"]}}